

Behaviour Of Fetal Haemoglobin And Its Correlation To Haemoglobin A1c Levels In Sudanese Adult Insulin-Dependent Diabetes Mellitus Patients

Sahar Elbager G¹*, Tahani Abbas A², Mahir Mohamed E¹, Rania Ahmed H¹, Sana Abdalla E³, Adil Babiker A¹

¹Department of Haematology, Faculty of Medical Laboratory Sciences, University of Medical Sciences and Technology, Sudan

²Department of Haematology, Faculty of Medical Laboratory Sciences, University of Karary, Sudan

³Department of Pathology, Faculty of Medicine, Al Neelain University, Sudan

* Corresponding author email: Saharelbagir@ymail.com

ABSTRACT

Aims: To estimate the fetal haemoglobin (HbF) in diabetes mellitus patients and its correlation to haemoglobin A1c levels as it is one of the effective diagnostic tools used in monitoring of diabetic patients.

Study design: Analytical, laboratory, hospital-based, cross-sectional study.

Place and Duration of Study: The study was carried out during the period March-June 2013. In Dreby Diabetic Centre, Khartoum, Khartoum State.

Methodology: A total of 150 samples were obtained; 50 insulin dependent diabetic patients, 50 non-insulin-treated diabetic patients and 50 control subjects with the same age and sex distribution. Hb A1c was estimated by ion exchange method and HbF was estimated by alkaline denaturation methods.

Results: Results showed significant increase in HbF and HbA1c in insulin-dependent diabetes (IDDM) in comparison to normal control ($p < 0.05$). Strong positive correlation between the Hb F level and duration of treatment per year, ($R = 0.961$) and weak negative correlation between Hb F level and Hb Alc in IDDM ($R = -0.436$). Strong negative correlation between Hb F level and Hb Alc according to duration of insulin treatment in IDDM, ($R = 0.964$, $R^2 = 0.929$, $p < 0.05$). There was weak negative correlation between Hb F level and Hb Alc according to age in IDDM, ($R = 0.580$, $R^2 = 0.337$, $p < 0.05$).

Conclusion: It is noted in this study, the high level of HbF accompanied by a decrease in Hb A1c level, thus HbF must be considered when A1C measured by ion exchange method and when comparing it with other measures of glycaemic control.

Keywords: fetal hemoglobin, HbA1c, diabetes mellitus, type 1 diabetes, type 2 diabetes, (HPLC)

1. INTRODUCTION

Diabetes, the most common non-communicable disease in Sudan, is having an increasing impact on rates of morbidity and mortality in Sudan[1-4].The spread of sedentary lifestyles and adoption of western dietary habits – high in refined carbohydrates and fat – are driving an increase in the number of people with obesity-related type 2 diabetes. Knowledge of the diabetes epidemic in Sudan is limited. The most recent data come from a small-scale study that was carried out in 1996, the results of the study indicated a prevalence of 3.4%.[4] The major complications of diabetes occur as result of hyperglycemia which is the major source of morbidity and mortality in both type 1(IDDM) and type 2 diabetes(NIDDM). The harmful of hyperglycemia divided into macrovascular complications (coronary artery disease, peripheral arterial disease and stroke) and microvascular complications (diabetic nephropathy, neuropathy and retinopathy) [5]. Diabetes Control and Complications Trial (DCCT)[6] and the United Kingdom Prospective Diabetes Study (UKPDS) [7] demonstrated conclusively that risks for complications are related directly to glycemic control, as measured by HbA1c.

In longer hyperglycaemia, more glucose molecules attach to the N-terminus of valine residue of the β -globin chain haemoglobin in red blood cells, thus the more glucose binds to red blood cell the higher is the glycosylated haemoglobin. Glycation can also occurs on the lysine residue either on the α or β chains.[8,9]Once a haemoglobin molecule is glycated, it remains that way and glycosylated haemoglobin will accumulate within the red cell, therefore, HbA1c level reflects the average level of glucose concentration in the preceding 2 to 3 months, the average erythrocyte lifespan[10,11].Regular measurements of haemoglobinA1c lead to changes in diabetes treatment and improvement of metabolic control, indicated by a lowering of haemoglobin A1c values [12].

The accuracy of HbA1c methods can be affected adversely by the presence of haemoglobin variants[13-16]. In addition,elevated levels of foetal haemoglobin (HbF) may interfere with HbA_{1c} measuremen [17-21]. Fetal haemoglobin (HbF, $\alpha_2\gamma_2$) is the main type of haemoglobin of the fetus and newborn. Normally in the second trimester, γ chain production (and Hb F levels) decrease and β chain production increases, resulting in increasing levels of hemoglobin A (Hb A), the major normal adult hemoglobin ($\alpha_2\beta_2$).Normal adults have less than 1% of HbF [22]. Elevated HbF levels can occur in patients as a result of pathologic conditions e.g. (Leukemia, anaemia, and Thalassemia) or a hereditary persistence of fetal haemoglobin.[22] HbF it glycated at lysine residues of γ -chain because it has no β chain. Glycation of HbF is approximately one-third that of HbA.[23,24]

Some published studies reported elevated foetal haemoglobin (HbF) levels in insulin-dependent diabetes mellitus (IDDM).[25-28] Thus, physicians must be aware that of existence of these conditions and it is potential interference when interpreting HbA1c.

In the present study, we describe the behaviour of fetal haemoglobin in diabetes mellitus patients and its Correlation to haemoglobin A1c levels as it one of the effective diagnostic tools used in monitoring of diabetic patients.

2. MATERIAL AND METHODS

2.1 Data collection: Data was collected using designed interview based questionnaire to obtain general information about patient (Age and gender), clinical information.

2.2 Study population: The study was carried out among patients diagnosed with Type1 (Insulin-dependent diabetes mellitus) diabetic patients who have been under insulin treatment for more than 15 years and Type 2 (Non-insulin-dependent diabetes mellitus).

2.3 Inclusion criteria: Diabetic patient male and female (40 years old or more, whose HbA1c values differed significantly from the expected results) were included. 3 had a value higher than expected and 47 had HbA1c values lower than expected

2.4 Exclusion criteria: Adult diabetic patients already diagnosed with (Haemoglobinopathy, Renal failure, Leukaemia, anaemia, Thalassaemia and Hereditary persistence of foetal haemoglobin, etc) were excluded.

2.5 Blood sample collection and analysis: Under a septic condition 2.5 milliliters venous blood was collected in Ethylenediaminetetra acetic acid (EDTA). Haemolysate prepared immediately and tests done within 4 Hours. HbA1c measured with a high-performance liquid chromatography (HPLC) ion-exchange analyzer[29].Kit manufactured by BioSystems code 1104.[30] Hb F was estimated by : Modified BETKE method .[31]

3. RESULTS

Table 1 shows mean $\pm$ St. Dev. of HbA1C% ,in IDDM group was found to be $7.2 \pm 1.2\%$ St. Dev. and in the control group $5.5 \pm 0.7\%$; this difference was found to be statistically significant ($P= 0.02$). In NIDDM ,The mean $\pm$ St. Dev. of HbA1C% was found to be $8.1 \pm 0.4\%$ St. Dev. and in control group 5.5 ± 0.7 , this difference is statistically significant ($P= 0.02$).The mean HbF levels , in IDDM group was found to be $2.38\% \pm 2.1$ St. Dev., in control subjects it was found to be $0.6\% \pm 0.3$;these differences were found to be statistically significant ($P = 0.000$). In the NIDDM group the mean of HbF was found to be $0.7 \pm 0.4\%$ and in the normal control subjects it was $0.6 \pm 0.3\%$ and these differences were found to be statistically insignificant at ($P = 0.33$).

Table 1: Mean and standard deviation of haemoglobin A1c %and HbF % among the study groups

Parameter (unit)	Study group			P-value
	IDDM n=50(A)	NIDDM n=50(B)	Control group n=50(C)	
HbA1c %	7.2 ± 1.2	8.1 ± 0.4	5.5 ± 0.7	A vs. C ; $P=0.025$; B vs.C ; $P=0.022$
HbF %	2.38 ± 2.1	0.7 ± 0.4	$0.6\% \pm 0.3$	A vs. C ; $P=0.000$; B vs.C ; $P=0.330$

Table 2 shows the mean of HbA1c in IDDM male subjects was found to be 7.1%, while it was found to be 7.2% in female subjects and this difference was found to be statistically insignificant($P=0.85$). In the male subjects with NIDDM, the mean of HbA1c level was found to be 8.1 ± 0.4 St. Dev. and in female subjects it was found to be 8.1 ± 0.4 a difference found to be statistically insignificant ($P=0.91$). For HbF %, In IDDM male subjects, the mean of HbF was found to be $2.8\% \pm 2.3$ St. Dev. and in female subjects it was 2.7 ± 2.4 . The difference between the two groups was found to be statistically insignificant ($P=0.83$). In the NIDDM male subjects, the mean of HbF was found to be 0.7 ± 0.3 St. Dev., in female subjects it was 0.8 ± 0.2 . The difference between the two groups was found to be statistically insignificant ($P=0.70$).

Table 2: Mean and standard deviation of HbA1c% and HbF % in IDDM and NIDDM subjects further classified by gender

Parameter classified by gender						
Parameter (unit)	Study groups				P-value	
	IDDM n=50		NIDDM n=50			
	Male	Female	Male	Female	IDDM	NIDDM
HbA1c %	7.1±1.2	7.3±1.1	8.1±0.4	8.1±0.4	0.859	0.914
HbF %	2.8±2.3	2.7±2.4	0.7±0.3	0.8±0.2	0.832	0.707

Table3 shows mean of HbA1c% in IDDM patients, In group had HbA1c % higher than expected(age 40-44 years) mean was found to be 7.9%, in the group had HbA1c % lower than expected (45-49 years) it was found to be 7.3% and in age group 50-54 years it was

found to be 5.8%; this difference was found to be statistically significant ($P= 0.02$). For HbF%, In group had HbA1c % higher than expected (age 40-44 years) mean was found to be 0.8%, in the group had HbA1c % lower than expected (45-49 years) it was found to be 2% and in age group 50-54 years it was found to be 4.2%; this difference was found to be statistically significant ($P= 0.002$).

Table 3: Mean of HbA1c% and HbF% in IDDM groups further classified according to unexpected HbA1c results

IDDM group				
Parameter (unit)	Patient had HbA1c % higher than expected	Patient had HbA1c % lower than expected		P-value
	Age (40-44) n=3	Age(45-49) n=40	Age (50-54) n=40	
HbA1C %	7.9±0.6	7.3±1	5.8±1.5	0.025
Hb F%	0.8±0.1	2±0.9	4.2±2	0.002

Regarding the duration of insulin treatment in years, the mean of HbA1c% in case group (IDDM) in the group subjected to insulin treatment of 15-23 years was found to be 7.9%, in the age group of 24-32 years it was 6.1% and in the age group 33-42 years was 4.7% ; these differences were found to be statistically significant ($P=0.04$). For HbF%, in the group subjected to insulin treatment for a duration of 15-23 years was found to be 0.8%, in the group subjected to treatment for a duration of 24-32 years it was found to be 3.8% and in group subjected to insulin treatment for a duration of 33-42 years it was found to be 7.1%. The differences between these groups were found to be statistically significant ($P=0.02$). In NIDDM the mean of HbA1c% in the age group subjected to treatment of 1-4 years was found to be 8.2%, in the group of 5-9 years it was 8.1% and in the group 10-14 years was 8.0% ; these differences were found to be statistically insignificant ($P=0.92$). For HbF%, in the age group subjected to treatment of 1-4 years was found to be 0.5%, in the group of 5-9 years it was 0.6% and in the group 10-14 years was 0.4% ; these differences were found to be statistically insignificant ($P=0.73$). Table 4

Table 4: Mean of HbA1c% and HbF % according to the duration of treatment in IDDM and NIDDM group

Duration of treatment (in years)								
Parameter (unit)	Duration of insulin treatment (in years) IDDM			Duration of treatment (in years) NIDDM			P-value	
	(15-21) y	(22-32)y	(33-42)y	(1-4)y	(5-9)y	(10-14)y	IDDM	NIDDM
HbA1c %	7.9±0.5	6.1±1	4.7±0.4	8.2±0.3	8.1±0.4	8±0.5	0.040	0.921
HbF %	0.8±0.2	3.8±0.7	7.1±0.4	0.5±0.3	0.6±0.3	0.4±0.2	0.025	0.732

Analysis of correlations indicates that there is a statistically significant negative correlation between HbF level and HbA1c in IDDM, where $R = -0.964$, $R^2 = 0.929$ ($p\text{-value} = 0.000$). On the other hand there was a positive correlation between the HbF level and duration of treatment per year, where $R = 0.961$, $R^2 = 0.923$ ($P = 0.000$). Table 5

160 **Table5:** Correlation of HbF% level with HbA1c % and the duration of insulin treatment in years
 161 and in IDDM group
 162

Parameter	Study group (n=50)		P-value
	HbF%		
HbA1c %	Correlations (R) – 0.964	Regression (R2) 0.929	0.000
Duration of insulin treatment	0.961	0.923	0.000

163

164

4.DISCUSSION

165

Hemoglobin A1c (HbA1c) is used routinely in the management of diabetes, as it is related directly to risks for diabetic complications. The accuracy of some HbA1c methods can be affected adversely by the presence of hemoglobin variants or elevated levels of (HbF). It is important to consider hemoglobinopathy in patients when the HbA1c value does not correlate with clinical expectations.

166

167

In this study, we observed a direct correlation between HbF, age and duration of insulin treatment in IDDM. No significant differences were seen when result of Hb A1C and Hb F values were correlated to gender in IDDM patients. In NIDDM, HbF concentrations do not appear dependent on sex, or degree of glycemic control.

168

169

We observed significantly increased of HbF in subjects with IDDM than do NIDDM and control subjects. An increased of HbF levels been reported in IDDM subjects in many studies.[25-28]Increased proportions of HbF have been described in autoimmune diseases such as pernicious anemia and thyrotoxicosis. Because IDDM has an autoimmune component[32,33], increases in HbF concentrations may it is possibly be present.

170

171

There was a statistically significant negative correlation between HbF level and HbA1c in IDDM. We have observed lower levels of HbA1c in diabetic patients presented with high levels of HbF. The 47 patients with lower HbA1c results than expected had high levels of HbF. The 3 patients with higher HbA1c results than expected had normal levels of HbF. Elevated levels of HbF are reported to interfere with the HbA1c measurements by falsely decreasing the HbA1c results.[34,35] . The result may be falsely low because HbA1c (%) is expressed as HbA1c/total Hb or due to a lower glycated rate for HbF than HbA. Therefore, it is essential to eliminate HbF to reduce the possibility of any potential interference of HbA1c measurement. One way to eliminate the effect of HbF is to determine the HbA1c level corrected by HbF (HbF corrected HbA1c) by the formula: $HbA1c / (total\ Hb - HbF)$, resulting in the correction of an apparently low HbA level

172

173

Our study also intended to find a possible relationship between HbF level and the duration of insulin treatment (in years) in IDDM patients, we observed significant increase of HbF levels in the patient groups that had been under insulin-treatment for 24-32 and 33-42 years in compare to the group under treatment for 15-23 years. We found a positive correlation between the HbF level and duration of treatment per year. The mechanisms leading to high HbF levels in diabetes under insulin-treatment are unknown. It has been suggested that a reactivation of the γ -globin gene can be induced by insulin, thus increasing HbF levels in insulin-treated patients seems more possible [25,27,28]

174

175

176

4. CONCLUSION

177

This study demonstrates the presence of elevated HbF in IDDM patients compared to non-diabetic individuals. HbF was increased in IDDM accordance to the length of insulin treatment and age. Artificial decreasing in HbA1c placed patients at higher risk for complications of diabetes. Considering the tendency toward lower result values in Hb A1c level with elevation of the HbF , Thus HbF should be considered in the interpretation of Hb A1c results measured by iron exchange methods.

178

179

180

181

182

183

184

185

186

187

188

206 **RECOMMENDATIONS**

- 207 1. Laboratories should be aware of the limitations of their HbA1c method with respect
208 to interference with elevated HbF.
209 2. IDDM patients who are older than 42 years and on insulin therapy for more than 24
210 years whose HbA1c values differed significantly from the expected results are
211 recommended to be subjected for HbF screening before measuring HbA1c level.
212
213

214 **ACKNOWLEDGEMENTS**

215

216

217

218

219

220 **COMPETING INTERESTS**

221 The authors have declared that no conflict of interest exist.

222 **FUNDING**

223 The authors received no financial support for the research and/or authorship of this article.
224

225 **AUTHORS' CONTRIBUTIONS**

226 Sahar Elbager G designed and performed the research, collected and analyzed data, wrote
227 the protocol and wrote the manuscript; Tahani Mohammed A provide the technical
228 support ; Mahir Mohamed E performed the statistical analysis; Sana Abdalla E , Adil Babiker
229 A supervised the research. Adil Babiker review manuscript.
230

231 **CONSENT (WHERE EVER APPLICABLE)**

232 Informed consent was obtained from all participants prior to sample collection.
233

234 **ETHICAL APPROVAL (WHERE EVER APPLICABLE)**

235 Before commencement of the study, the protocol was approved by SUMASRI International
236 Review Board (SIRB) at University of Medical Sciences and Technology(UMST).
237

238 **REFERENCES**

239

- 240 1. Ahmed AM, Ahmed NH. Hospitalization patterns of diabetic patients in Sudan.
241 Diabetes Int 2000; 10: 18-9.
242 2. Ahmed AM, Ahmed NH, Abdalla ME. Pattern of hospital mortality among diabetic
243 patients in Sudan. Pract Diabetes Int 2000; 17: 41-3.
244 3. Ahmed AM. Diabetes mellitus in Sudan: size of the problem and possibilities of
245 efficient care. Pract Diabetes Int2001; 18: 324-7.
246 4. Elbagir M, Eltom MA. A population-based study on prevalence of diabetes in
247 northern Sudan. Diabetes Care1996; 24: 1126-8
248 5. Michael J. Fowler, MD. Microvascular and Macrovascular Complications of
249 Diabetes. Clinical Diabetes July 1, 2011 vol. 29 no. 3 116-122
250 6. The Diabetes Control and Complications Trial Research Group. The Effect of
251 Intensive Treatment of Diabetes on the Development and Progression of Long-Term
252 Complications in Insulin-Dependent Diabetes Mellitus.N Engl J Med 1993; 329:977-
253 986.
254 7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control
255 with sulphonylureas or insulin compared with conventional treatment and risk of

256 complications in patients with type 2 diabetes (UKPDS 33). *Lancet*.
257 1998;352(9131):837-53

258 8. Lapolla A, Molin L, Traldi P. Protein glycation in diabetes as determined by mass
259 spectrometry. *Int J Endocrinol* 2013;2013:11.

260 9. Goodall I. HbA1c standardisation destination—global IFCC Standardisation. How,
261 why, where and when—a tortuous pathway from kit manufacturers, via
262 interlaboratory lyophilized and whole blood comparisons to designated national
263 comparison schemes. *Clin Biochem Rev/Aust Assoc Clin Biochem* 2005;26:5–19.

264 10. Goldstein DE, Little RR, Wiedmeyer H, England JD & Mackenzie EM (1986).
265 Glycated hemoglobin: methodologies and clinical applications. *Clinical Chemistry*,
266 32 (Suppl 1): B64-B70.

267 11. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD & Izlar C (1994). Glycohemoglobin
268 measured by automated affinity HPLC correlates with both short-term and longterm
269 antecedent glycemia. *Clinical Chemistry*, 40: 1317-1321.

270 12. King H, Rewers M. World Health Organization Ad Hoc Diabetes Reporting Group.
271 Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance
272 in adults. *Diabetes Care* 1993;16:157-177.

273 13. Mongia SK, Little RR, Rohlfing CL, et al Effects of hemoglobin C and S traits on the
274 results of 14 commercial glycated hemoglobin assays. *Am J Clin*
275 *Pathol*. 2008;130:136–140

276 14. Rohlfing C, Hanson S, Weykamp C, Siebelder C, Higgins T, Molinaro R, Yip PM,
277 Little R. Effects of hemoglobin C, D, E and S traits on measurements of hemoglobin
278 A1c by twelve methods. *Clin Chim Acta* 2016, 455:80-83.

279 15. Lin CN, Emery T, Little RR, Hanson SE, Rohlfing CL, Jaissonc S, Gillery P, Roberts
280 WL. Effects of hemoglobin C, D, E, S traits on measurements of HbA1c by six
281 methods. *Clin Chim Acta* 2012;413: 819-21

282 16. Little RR, Rohlfing CR, Hanson S, Connolly S, Higgins T, Weykamp C, D'Costa M,
283 Luzzi V, Owen WE, Roberts WL. Effects of hemoglobin E and D traits on glycated
284 hemoglobin (HbA1c) Measurements by twenty-three methods. *Clin Chem*
285 2008;54:1277-82.

286 17. Rohlfing CL, Connolly SM, England JD, Hanson SE, Moellering CM, Bachelder JR
287 and Little RR. The effect of elevated Fetal hemoglobin on hemoglobin A1c results.
288 *American Journal of Clinical Pathology*, 2008; 129: 811-814.

289 18. Shu I, Devraj S, Hanson SE, Wang P. Comparison of hemoglobin A1c
290 measurements of samples with elevated fetal hemoglobin by three commercial
291 assays. *Clinica Chimica Acta*, 2012; 413: 1712-1713.

292 19. Little RR, Rohlfing CL, Hanson SE, Schmidt RL, Lin Chia-Ni, Madsen RW, Roberts
293 WL. The effect of increased Fetal hemoglobin on 7 common HbA1c assay methods.
294 *Clinical Chemistry*, 2012; 58(5): 945-947.

295 20. Nitta T, Yamashiro Y, Hattori Y, Ezumi T, Nishioka M, Nakamura J. The
296 interference by HbF on HbA1c (BM test HbA1c) measurements in enzymatic
297 method. *Annals of Clinical Biochemistry*, 2015; Jan 13. pii: 0004563214568872.

298 21. Felner EI, McGrath M. Inaccurate hemoglobin A1C levels in patients with type 1
299 diabetes and hereditary persistence of hemoglobin F. *J Pediatr* 2008; 153: 137–139.

300

- 301 22. A.V Hoffbrand. Erythropoiesis and general aspects of anaemia in Essential
302 Haematology ;2006 p16.
- 303 23. Cas Weykamp. HbA1c: A Review of Analytical and Clinical Aspects. Ann Lab Med.
304 2013 Nov; 33(6): 393–400
- 305 24. Little RR, Roberts WL.A review of variant hemoglobins interfering with hemoglobin
306 A1c measurement. J Diabetes Sci Technol. 2009;3:446–451
- 307 25. Koskinen L, Koivula T, Lahtela J: Fetal hemoglobin in diabetic patients. Diabetes
308 Care 17:828-831, 1994.
- 309 26. Kilpatrick Michael Small, Alan Rumley, and Marek H.Dominiczak, increased fetal
310 haemoglobin in insulin-treated diabetes mellitus contribute to the imprecision
311 glycohaemoglobin measurements, CLIN. CHEM 39/5, 833-835, 1993.
- 312 27. Diem P et al ,Fetal haemoglobin levels in adult type 1 (insulin-
313 dependent) diabetic patients, Diabetologia . 36(2):129-32,1993.
- 314 28. Pardini et al , Fetal hemoglobin levels are related to metabolic control
315 in diabetic subjects, Brazil J Med Biol Res.32(6):695-701,1999.
- 316 29. Davis JE, McDonald JM, Jarett L. A high-performance liquid chromatography
317 method for hemoglobin A1c. Diabetes 1978 Feb;27(2):102-7.
- 318 30. BIOCHEMISTRY | Biosystems .**HbA1c measured with** a high-performance liquid
319 chromatography (HPLC).
- 320 Available: [http://www.biolinker.com.ar/productos/PDF_BIO/11044-11045%20](http://www.biolinker.com.ar/productos/PDF_BIO/11044-11045%20Hemoglobina%20A1c.pdf)
321 [Hemoglobina %20A1c.pdf](http://www.biolinker.com.ar/productos/PDF_BIO/11044-11045%20Hemoglobina%20A1c.pdf)
- 322 31. Barbara J Bain, Imelda Bates, Michael A Laffan and S. Mitchell Lewis. Investigation
323 of abnormal haemoglobins and thalassaemi in Dacie and Lewis. Practical
324 Haematology,2011 p.326.
- 325 32. Potter KN, Wilkin TJ. The molecular specificity of insulin autoantibodies. Diabetes
326 Metab Res Rev. 2000 Sep-Oct;16(5):338-53.
- 327 33. Bluestone JA, Herold K, Eisenbarth GG,et al. "Genetics, pathogenesis and clinical
328 interventions in type 1 diabetes". Nature 2010;464 (7293): 1293–1300.
- 329 34. Rohlfing CL, Connolly SM, England JD, et al. The effect of elevated fetal hemoglobin
330 on hemoglobin A1c results: five common hemoglobin A1c methods compared with
331 the IFCC reference method. Am J Clin Pathol. 2008;129(5):811-814
- 332 35. Chu CH, Lam HC, Lee JK, Wang MC, Lu CC, Sun CC, Chuang MJ. Common
333 hemoglobin variants in southern Taiwan and their effect on the determination of
334 HbA1c by ion-exchange high-performance liquid chromatography. J Chin Med
335 Assoc. 2009 Jul;72(7):362-7

336 ABBREVIATIONS

DCCT Diabetes Control and Complications Trial

Hb F Fetal haemoglobin

HbA1c Hemoglobin A1c

HPLC High-Performance Liquid Chromatography

IDDM Insulin-Dependent Diabetes Mellitus

NIDDM Non-Insulin-Dependent Diabetes Mellitus

UKPDS United Kingdom Prospective Diabetes Study

339

340

341

342 **APPENDIX**

343

344